| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | 28.3 | 59.5 |
| Net income | 18.4 | 48.4 |
| EPS (diluted, $ a share) | $0.43 | $1.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -62.0% |
|---|
10-Q filed with the SEC, NASDAQ: ORMP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Oramed Pharmaceuticals Inc.: key numbers
- Share price
- $3.90Close, Nov 16
- Market cap
- $170M
- Shares outstanding
- 43.49MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Oramed Pharmaceuticals Inc.
All →Oramed Pharmaceuticals CFO Avraham Gabay Sells $90.2K of Stock
Avraham Gabay, CFO, sold 20,000 shares of Oramed Pharmaceuticals Inc. at $4.51 a share, worth $90.2K in total on Oct 1, 2026. Shares held after the trade: 861,076 (-2.3%).
- Value
- $90.2K
- Shares
- 20,000
- Price
- $4.51
- Role
- CFO
- Holding change
- -2.3%
- Trade date
- Oct 1, 2026
Oramed Pharmaceuticals COO & Cbo Joshua Hexter Sells $135K of Stock
Joshua Hexter, COO & Cbo, sold 30,000 shares of Oramed Pharmaceuticals Inc. at $4.51 a share, worth $135K in total on Oct 1, 2026. Shares held after the trade: 1,328,130 (-2.2%).
- Value
- $135K
- Shares
- 30,000
- Price
- $4.51
- Role
- COO & Cbo
- Holding change
- -2.2%
- Trade date
- Oct 1, 2026
Oramed Pharmaceuticals Shareholder Meeting
Oramed Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 15, 2026, where shareholders re-elected six directors and ratified Kesselman & Kesselman as the independent auditor. Stockholders also approved an amendment to the 2019 Stock Incentive Plan to increase the authorized share pool by 3,000,000 shares and voted to hold future say-on-pay votes every three years.